CODX - Co-Diagnostics Inc Stock Price, Fair Value and News

1.10USD-0.04 (-3.51%)Delayed

Market Summary

USD1.10-0.04

Delayed

-3.51%

CODX Stock Price

View Fullscreen

CODX RSI Chart

CODX Valuation

Market Cap

34.4M

Price/Earnings (Trailing)

-0.88

Price/Sales (Trailing)

5.15

EV/EBITDA

-0.3

Price/Free Cashflow

-1.29

CODX Price/Sales (Trailing)

CODX Profitability

Operating Margin

41.34%

EBT Margin

-589.77%

Return on Equity

-49.63%

Return on Assets

-44.87%

Free Cashflow Yield

-77.49%

CODX Fundamentals

CODX Revenue

Revenue (TTM)

6.7M

Rev. Growth (Yr)

-41.49%

Rev. Growth (Qtr)

-86.84%

CODX Earnings

Earnings (TTM)

-38.9M

Earnings Growth (Yr)

-61.8%

Earnings Growth (Qtr)

36.55%

Breaking Down CODX Revenue

Last 7 days

-0.9%

Last 30 days

-3.5%

Last 90 days

-5.2%

Trailing 12 Months

-17.9%

How does CODX drawdown profile look like?

CODX Financial Health

Current Ratio

10.19

CODX Investor Care

Shares Dilution (1Y)

3.35%

Diluted EPS (TTM)

-1.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.7M	0	0	0
2023	27.4M	20.5M	13.7M	6.8M
2022	100.6M	78.2M	53.2M	34.2M
2021	93.0M	96.3M	104.6M	97.9M
2020	0	0	0	74.6M
2019	0	0	0	0
2018	15.7K	23.8K	31.8K	39.9K
2017	0	0	0	7.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Co-Diagnostics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 23, 2023	serbin richard s	acquired	-	-	30,000	-
Nov 23, 2023	egan dwight h	acquired	-	-	150,834	chief executive officer
Nov 23, 2023	nelson james b	acquired	-	-	30,000	-
Nov 23, 2023	brown brian lee	back to issuer	-45,517	1.26	-36,125	chief financial officer
Nov 23, 2023	brown brian lee	acquired	-	-	118,332	chief financial officer
Nov 23, 2023	egan dwight h	back to issuer	-58,019	1.26	-46,047	chief executive officer
Nov 23, 2023	murphy ted	acquired	-	-	30,000	-
Nov 23, 2023	durenard eugene	acquired	-	-	30,000	-
May 23, 2023	durenard eugene	acquired	-	-	18,333	-
May 23, 2023	egan dwight h	acquired	-	-	105,000	chief executive officer

Which funds bought or sold CODX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-63,055	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-57,309	305,648	0.01%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-24.54	-46,858	81,683	-%
May 15, 2024	D. E. Shaw & Co., Inc.	unchanged	-	-9,724	51,862	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-21,136	112,725	-%
May 15, 2024	MORGAN STANLEY	reduced	-8.34	-5,690	19,251	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-27.00	-	-%
May 15, 2024	Kestra Advisory Services, LLC	added	7.46	-17,533	166,814	-%
May 15, 2024	Man Group plc	reduced	-85.64	-86,633	11,913	-%
May 15, 2024	Royal Bank of Canada	reduced	-94.15	-1,000	-	-%

Are Funds Buying or Selling CODX?

Are funds buying CODX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CODX

No. of Funds

Unveiling Co-Diagnostics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.82%	1,781,283	SC 13G/A
Feb 09, 2023	vanguard group inc	5.76%	1,781,283	SC 13G/A
Feb 09, 2022	vanguard group inc	5.30%	1,795,057	SC 13G/A
Jul 12, 2021	blackrock inc.	1.8%	517,938	SC 13G/A
Feb 10, 2021	vanguard group inc	5.71%	1,613,884	SC 13G
Feb 02, 2021	blackrock inc.	6.8%	1,921,670	SC 13G
Jan 04, 2021	sabby management, llc	12.%	0	SC 13G/A
Feb 10, 2020	cvi investments, inc.	0%	0	SC 13G/A
Jan 28, 2020	sabby management, llc	6.63%	1,379,311	SC 13G
Jan 03, 2020	sabby management, llc	12.%	0	SC 13G/A

Recent SEC filings of Co-Diagnostics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Apr 29, 2024	4	Insider Trading
Mar 20, 2024	3	Insider Trading

Peers (Alternatives to Co-Diagnostics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Co-Diagnostics Inc News

Latest updates

Co-Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-86.8%	468	3,555	2,457	198	800	1,401	5,094	5,023	22,699	20,401	30,101	27,358	20,025	27,145	21,819	24,040	1,549	795	41.00	62.00	36.00
Cost Of Revenue	-92.1%	235	2,968	256	459	502	516	768	915	3,282	2,487	3,311	2,504	3,273	4,313	5,821	5,975	482	53.00	20.00	39.00	452*
Gross Profit	-60.3%	233	587	2,201	-261	100	886	4,327	4,108	19,417	17,915	26,790	24,854	16,752	22,832	15,997	18,065	1,067	56.00	21.00	23.00	3.00
Operating Expenses	-15.5%	10,493	12,413	11,137	11,733	10,050	27,007	10,862	8,255	9,593	7,606	13,160	13,063	6,417	6,803	3,959	3,357	2,149	1,679	1,671	1,389	1,257
S&GA Expenses	3.1%	1,564	1,517	1,904	1,733	1,706	1,330	1,890	1,472	2,652	2,094	4,253	5,853	1,198	3,208	798	390	268	291	262	252	256
R&D Expenses	-8.1%	5,680	6,179	5,789	5,981	5,014	4,739	5,037	3,890	3,771	2,182	5,893	4,669	2,217	1,113	922	750	400	381	331	313	347
EBITDA Margin	-5.5%	-5.71*	-5.41*	-3.74*	-2.26*	-1.41*	-0.51*	0.33*	0.44*	0.49*	0.47*	0.49*	0.53*	0.58*	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	91.00	-	-	15.00
Income Taxes	-99.4%	23.00	3,834	-2,113	-2,238	-2,259	-3,138	-2,114	-741	1,386	2,746	2,101	2,145	1,986	-	-2,914	-	-	-	-	-	-
Earnings Before Taxes	14.3%	-9,289	-10,842	-8,095	-11,157	-8,015	-25,044	-3,475	-3,427	13,101	10,244	13,577	11,930	9,885	15,812	12,817	15,005	-1,065	-1,735	-1,747	-1,344	-1,368
EBT Margin	-5.4%	-5.90*	-5.59*	-3.83*	-2.32*	-1.46*	-0.55*	0.31*	0.43*	0.49*	0.47*	0.49*	0.52*	0.58*	-	-	-	-	-	-	-	-
Net Income	36.6%	-9,312	-14,676	-5,982	-8,918	-5,755	-21,905	-1,361	-2,686	11,715	7,498	11,476	9,785	7,899	12,807	15,732	15,005	-1,065	-1,735	-1,747	-1,344	-1,368
Net Income Margin	-12.3%	-5.82*	-5.19*	-3.11*	-1.85*	-1.16*	-0.42*	0.28*	0.36*	0.40*	0.37*	0.40*	0.48*	0.55*	-	-	-	-	-	-	-	-
Free Cashflow	-69.6%	-8,892	-5,243	-6,831	-5,693	-5,679	-4,303	888	1,147	7,409	4,757	11,343	12,182	12,130	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.1%	87.00	95.00	109	113	117	123	148	161	171	160	105	93.00	81.00	71.00	55.00	39.00	20.00	2.00	4.00	5.00	6.00
Current Assets	-13.6%	54.00	62.00	71.00	77.00	86.00	93.00	102	115	125	115	102	90.00	79.00	68.00	52.00	37.00	20.00	2.00	3.00	5.00	6.00
Cash Equivalents	54.9%	23.00	15.00	10.00	14.00	6.00	23.00	82.00	86.00	97.00	89.00	83.00	70.00	58.00	43.00	21.00	19.00	17.00	1.00	3.00	4.00	5.00
Inventory	-6.9%	2.00	2.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	2.00	3.00	4.00	6.00	8.00	11.00	10.00	1.00	0.00	0.00	0.00	0.00
Net PPE	4.9%	3.00	3.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	-	-	-	-	-	-	-	15.00	15.00	15.00	15.00	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-10.6%	8.00	9.00	9.00	9.00	6.00	9.00	13.00	16.00	23.00	26.00	5.00	6.00	5.00	5.00	2.00	3.00	1.00	0.00	0.00	1.00	1.00
Current Liabilities	-8.3%	5.00	6.00	5.00	5.00	4.00	4.00	6.00	7.00	13.00	13.00	4.00	5.00	4.00	4.00	2.00	3.00	1.00	0.00	0.00	0.00	0.00
Shareholder's Equity	-8.9%	78.00	86.00	99.00	103	111	115	135	144	148	134	100	87.00	76.00	67.00	53.00	36.00	19.00	2.00	3.00	5.00	6.00
Retained Earnings	-202.5%	-4.71	5.00	19.00	25.00	34.00	40.00	62.00	63.00	66.00	54.00	47.00	35.00	25.00	18.00	5.00	-11.03	-26.03	-24.97	-23.15	-21.41	-20.06
Additional Paid-In Capital	1.6%	98.00	97.00	95.00	93.00	91.00	88.00	86.00	84.00	82.00	80.00	53.00	52.00	51.00	49.00	48.00	47.00	45.00	27.00	26.00	26.00	26.00
Shares Outstanding	0.1%	31.00	31.00	31.00	31.00	31.00	31.00	32.00	32.00	34.00	34.00	29.00	29.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	33.00	-	-	-	187	-	-	-	229	-	-	-	485	-	-	-	10.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-77.7%	-8,490	-4,778	-6,594	-5,209	-5,499	-4,009	1,118	1,654	7,806	4,878	11,509	12,424	12,270	19,958	8,556	987	-1,335	-1,612	-1,215	-1,328	-1,368
Share Based Compensation	-14.0%	1,571	1,826	2,172	2,170	2,169	2,404	2,230	1,533	1,375	1,658	1,411	927	1,513	571	1,238	302	433	276	276	126	88.00
Cashflow From Investing	73.4%	16,673	9,615	3,170	13,237	-10,632	-53,306	4,739	-10,459	859	1,071	870	-234	2,393	1,246	-6,150	-669	-250	-38.78	-96.69	-227	-72.00
Cashflow From Financing	100.0%	-	-159	-166	-555	-482	-1,217	-10,394	-2,571	150	-	5.00	296	149	543	275	863	18,062	-	-	-	5,903
Buy Backs	-100.0%	-	160	166	556	482	-	10,395	2,599	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CODX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 467,854	$ 601,957
Cost of revenue	234,505	502,241
Gross profit	233,349	99,716
Operating expenses
Sales and marketing	1,563,682	1,706,331
General and administrative	2,918,803	3,013,965
Research and development	5,679,678	5,014,060
Depreciation and amortization	330,573	316,010
Total operating expenses	10,492,736	10,050,366
Loss from operations	(10,259,387)	(9,950,650)
Other income, net
Interest income	362,733	202,372
Realized gain on investments	228,070	418,082
Gain on remeasurement of acquisition contingencies	450,260	1,037,672
Gain (loss) on equity method investment in joint venture	(70,955)	277,322
Total other income, net	970,108	1,935,448
Loss before income taxes	(9,289,279)	(8,015,202)
Income tax provision (benefit)	22,764	(2,259,811)
Net loss	(9,312,043)	(5,755,391)
Other comprehensive loss
Change in net unrealized gains on marketable securities, net of tax	79,855	178,621
Total other comprehensive income	79,855	178,621
Comprehensive loss	$ (9,232,188)	$ (5,576,770)
Loss per common share:
Basic	$ (0.31)	$ (0.20)
Diluted	$ (0.31)	$ (0.20)
Weighted average shares outstanding:
Basic	29,842,874	29,483,540
Diluted	29,842,874	29,483,540
Product Revenue [Member]
Total revenue	$ 252,745	$ 601,957
Grant Revenue [Member]
Total revenue	$ 215,109

CODX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 23,099,251	$ 14,916,878
Marketable investment securities	26,864,435	43,631,510
Accounts receivable, net	434,868	303,926
Inventory, net	1,549,812	1,664,725
Income taxes receivable		26,955
Prepaid expenses and other current assets	1,750,467	1,597,114
Total current assets	53,698,833	62,141,108
Property and equipment, net	3,183,116	3,035,729
Operating lease right-of-use asset	2,758,757	2,966,774
Intangible assets, net	26,328,000	26,403,667
Investment in joint venture	702,427	773,382
Total assets	86,671,133	95,320,660
Current liabilities
Accounts payable	2,027,607	1,482,109
Accrued expenses	1,324,779	2,172,959
Operating lease liability, current	859,912	838,387
Contingent consideration liabilities, current	750,877	891,666
Deferred revenue	306,477	362,449
Total current liabilities	5,269,652	5,747,570
Long-term liabilities
Income taxes payable	679,018	659,186
Operating lease liability	1,931,164	2,152,180
Contingent consideration liabilities	438,638	748,109
Total long-term liabilities	3,048,820	3,559,475
Total liabilities	8,318,472	9,307,045
Commitments and contingencies (Note 10)
Stockholders’ equity
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,127,096 shares issued and 31,278,418 shares outstanding as of March 31, 2024 and 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023	36,127	36,108
Treasury stock, at cost; 4,848,678 shares held as of March 31, 2024 and December 31, 2023, respectively	(15,575,795)	(15,575,795)
Additional paid-in capital	98,379,651	96,808,436
Accumulated other comprehensive income	226,555	146,700
Accumulated earnings (deficit)	(4,713,877)	4,598,166
Total stockholders’ equity	78,352,661	86,013,615
Total liabilities and stockholders’ equity	$ 86,671,133	$ 95,320,660

About Co-Diagnostics Inc

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Dwight H. Egan
WEBSITE	codiagnostics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	145

Co-Diagnostics Inc Frequently Asked Questions

What is the ticker symbol for Co-Diagnostics Inc? What does CODX stand for in stocks?

CODX is the stock ticker symbol of Co-Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Co-Diagnostics Inc (CODX)?

As of Fri May 17 2024, market cap of Co-Diagnostics Inc is 34.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CODX stock?

You can check CODX's fair value in chart for subscribers.

What is the fair value of CODX stock?

You can check CODX's fair value in chart for subscribers. The fair value of Co-Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Co-Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CODX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Co-Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether CODX is over valued or under valued. Whether Co-Diagnostics Inc is cheap or expensive depends on the assumptions which impact Co-Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CODX.

What is Co-Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CODX's PE ratio (Price to Earnings) is -0.88 and Price to Sales (PS) ratio is 5.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CODX PE ratio will change depending on the future growth rate expectations of investors.